In case you missed it, we announced the validation & clinical implementation of our CSF-01 Leptomeningeal Cancer Cell Diagnostic.
The CSF-01 cancer cell enumeration test is an exploratory endpoint in the ReSPECT-LM Phase 1 trial that has shown promise in the trial’s early cohorts.
In Phase 1/Part A of the ReSPECT-LM trial presented at the 2023 SNO/ASCO Meeting, it showed an average 53% reduction in CSF tumor cells 28 days after a single intrathecal administration of rhenium (186Re) obisbemeda in patients with LM.
Read Full Press Release: https://bit.ly/PSTV_PR
More About ReSPECT-LM: https://bit.ly/3lqkKBO
#BrainCancer #ClinicalTrials #BreastCancer #LungCancer #Oncology #Diagnostics
Recent Comments